Published in Transplantation on September 27, 2008
How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood (2010) 1.29
Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res (2010) 1.10
Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood (2008) 1.07
Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation. Sci Transl Med (2009) 0.83
CTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalk. Int Immunopharmacol (2013) 0.82
Induction of alloantigen-specific anergy in human peripheral blood mononuclear cells by alloantigen stimulation with co-stimulatory signal blockade. J Vis Exp (2011) 0.79
TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. Blood (2016) 0.76
Allospecific Tregs Expanded After Anergization Remain Suppressive in Inflammatory Conditions but Lack Expression of Gut-homing Molecules. Mol Ther (2016) 0.75
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 12.75
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med (1995) 10.04
A theory of self-nonself discrimination. Science (1970) 7.99
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
The B7 and CD28 receptor families. Immunol Today (1994) 6.38
Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med (1998) 5.71
Detection of intracellular cytokines by flow cytometry. J Immunol Methods (1993) 4.54
Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods (2000) 3.89
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity (1994) 3.73
Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med (1999) 3.72
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med (2003) 3.60
Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood (1999) 3.53
Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol (2005) 3.04
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol (1997) 2.79
Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med (1989) 2.61
Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med (1985) 2.30
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood (2006) 1.93
Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res (2001) 1.82
Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis (2000) 1.81
Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J Infect Dis (2002) 1.58
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood (2003) 1.55
Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood (1989) 1.52
Human CD28-CD8+ T cells contain greatly expanded functional virus-specific memory CTL clones. J Immunol (1999) 1.50
T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res (2005) 1.43
Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol (2004) 1.20
Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood (2004) 1.18
Properties of CD4(+) T cells in human cytomegalovirus infection. Hum Immunol (2004) 1.17
Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood (2003) 1.10
NK cells mediate costimulation blockade-resistant rejection of allogeneic stem cells during nonmyeloablative transplantation. Am J Transplant (2006) 1.09
Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res (2006) 1.06
Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant (2006) 1.03
Temporal dynamics of CD69 expression on lymphoid cells. J Immunol Methods (1997) 1.03
Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. Blood Cells Mol Dis (2004) 0.98
Haploidentical stem cell transplantation: the always present but overlooked donor. Hematology Am Soc Hematol Educ Program (2005) 0.97
Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings. Biol Blood Marrow Transplant (2004) 0.94
Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant (2004) 0.94
Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses. Blood (2002) 0.93
Canadian multicenter pilot trial of haploidentical donor transplantation. Blood Cells Mol Dis (2004) 0.89
The flow cytometric PKH-26 assay for the determination of T-cell mediated cytotoxic activity. Methods (2003) 0.88
Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. Br J Haematol (1993) 0.87
Blockade of CD86 and CD40 induces alloantigen-specific immunoregulatory T cells that remain anergic even after reversal of hyporesponsiveness. Blood (2000) 0.84
T cell depletion of HLA and haploidentical marrow reduces graft-versus-host disease but it may impair a graft-versus-leukemia effect. Transplant Proc (1987) 0.82
Human alloantigen-specific anergic cells induced by a combination of CTLA4-Ig and CsA maintain anti-leukemia and anti-viral cytotoxic responses. Bone Marrow Transplant (2001) 0.81
Treatment of leukemia with partially matched related bone marrow transplantation. Bone Marrow Transplant (1997) 0.80
Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation (2003) 5.07
Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med (2005) 3.19
Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med (2004) 2.32
Prize-based contests can provide solutions to computational biology problems. Nat Biotechnol (2013) 1.95
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood (2005) 1.89
Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol (2005) 1.78
Identification of an evolutionarily conserved transcriptional signature of CD8 memory differentiation that is shared by T and B cells. J Immunol (2008) 1.63
CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J Immunol (2002) 1.58
Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res (2005) 1.48
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma (2011) 1.44
Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res (2007) 1.44
Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood (2005) 1.43
Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res (2004) 1.42
Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med (2011) 1.37
Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant (2010) 1.34
CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood (2005) 1.17
CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res (2008) 1.11
Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res (2010) 1.10
IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. Blood (2003) 1.10
An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol (2007) 1.10
Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood (2008) 1.07
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res (2005) 1.06
Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin Cancer Res (2006) 1.06
HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol (2002) 1.06
Autoantibodies frequently detected in patients with aplastic anemia. Blood (2003) 1.05
Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood (2002) 1.04
Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. J Clin Oncol (2013) 1.03
Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant (2007) 1.02
pH-triggered microparticles for peptide vaccination. J Immunol (2004) 1.00
cAMP inhibits both Ras and Rap1 activation in primary human T lymphocytes, but only Ras inhibition correlates with blockade of cell cycle progression. Blood (2002) 0.99
Factors associated with parental activation in pediatric hematopoietic stem cell transplant. Med Care Res Rev (2011) 0.97
Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol (2003) 0.96
Common gamma chain-signaling cytokines promote proliferation of T-cell acute lymphoblastic leukemia. Haematologica (2004) 0.96
A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2004) 0.96
Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21. Clin Cancer Res (2008) 0.94
The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood (2003) 0.94
17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli. J Leukoc Biol (2011) 0.94
Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses. Blood (2002) 0.93
Correspondence re R. Lapointe et al., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836-43. Cancer Res (2004) 0.93
Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol (2005) 0.92
MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun (2003) 0.92
Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival. Exp Hematol (2006) 0.92
Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Res (2005) 0.91
Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help. PLoS One (2012) 0.91
Oral chronic graft-versus-host disease in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2005) 0.91
A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. Int Immunol (2010) 0.90
Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol (2011) 0.89
Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival. PLoS One (2011) 0.88
Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell. Clin Cancer Res (2011) 0.88
Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia. Blood (2005) 0.87
Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood (2006) 0.87
Measuring T cell immunity to influenza vaccination in children after haemopoietic stem cell transplantation. Br J Haematol (2004) 0.87
Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2005) 0.86
Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB. Blood (2005) 0.86
A multi-center, randomized, controlled trial of parenteral nutrition titrated to resting energy expenditure in children undergoing hematopoietic stem cell transplantation ("PNTREE"): rationale and design. Contemp Clin Trials (2010) 0.86
Prognostic factors in the resumption of oral dietary intake after allogeneic hematopoietic stem cell transplantation (HSCT) in children. JPEN J Parenter Enteral Nutr (2007) 0.86
Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation. Cell Transplant (2012) 0.83
IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells. J Immunol (2012) 0.83
Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation. Sci Transl Med (2009) 0.83
Dyskeratosis congenita vs. chronic graft versus host disease: report of a case and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2004) 0.83
Deficient expression of bactericidal/permeability-increasing protein in immunocompromised hosts: translational potential of replacement therapy. Biochem Soc Trans (2011) 0.83
Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients. Br J Haematol (2005) 0.83
Bone loss and vitamin D deficiency in children undergoing hematopoietic cell transplantation. Pediatr Blood Cancer (2015) 0.83
Effect of titrated parenteral nutrition on body composition after allogeneic hematopoietic stem cell transplantation in children: a double-blind, randomized, multicenter trial. Am J Clin Nutr (2011) 0.82
Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int J Cancer (2005) 0.81
Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin Cancer Res (2008) 0.81
Induction of alloantigen-specific anergy in human peripheral blood mononuclear cells by alloantigen stimulation with co-stimulatory signal blockade. J Vis Exp (2011) 0.79
Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. Leuk Lymphoma (2004) 0.79
Changing factors associated with parent activation after pediatric hematopoietic stem cell transplant. Support Care Cancer (2014) 0.77
Serum citrulline as a biomarker of gastrointestinal function during hematopoietic cell transplantation in children. J Pediatr Gastroenterol Nutr (2014) 0.77
Differential localization and function of ADP-ribosylation factor-6 in anergic human T cells: a potential marker for their identification. J Immunol (2003) 0.77
Neutrophil defense in patients undergoing bone marrow transplantation: bactericidal/permeability-increasing protein (BPI) and defensins in graft-derived neutrophils. Transplantation (2002) 0.76
Marrow failure. Hematology Am Soc Hematol Educ Program (2002) 0.76
Aplastic anemia in adolescents and young adults. Acta Haematol (2014) 0.76
Weekly measurements accurately represent trends in resting energy expenditure in children undergoing hematopoietic stem cell transplantation. JPEN J Parenter Enteral Nutr (2008) 0.75
Therapy for aplastic anemia. Hematology Am Soc Hematol Educ Program (2011) 0.75
Effect of weight on outcomes of children undergoing hematopoietic cell transplantation. Pediatr Hematol Oncol (2012) 0.75
Sweet syndrome in patients with Fanconi anaemia: association with extracutaneous manifestations and progression of haematological disease. Br J Haematol (2011) 0.75